Milan, Italy and Morristown, NJ, USA - May 29, 2020 - Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of
Pivotal trial did not meet primary or secondary efficacy variables
Newron will prioritize its Phase III development program of Evenamide in schizophrenia and evaluate additional
Milan, Italy – April 29, 2020 - Newron Pharmaceutical S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for
Milan, Italy – April 15, 2020 - Newron Pharmaceutical S.p.A. (“Newron”) (SIX: NWRN, XETRA:NP5), a biopharmaceutical company focused on the development of novel therapies for
Shareholders approve all motions on the agenda at the 2020 AGM
STARS study results for Rett syndrome remain on track
Start of forthcoming new clinical studies likely to be delayed
STARS (Sarizotan Treatment of Apneas in Rett Syndrome) clinical study to evaluate the effect of sarizotan in patients with Rett syndrome
Topline results from pivotal study on
Milan, Italy, March 5, 2020 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for
Milan, Italy and Morristown, NJ, USA, Feb. 17, 2020 -- Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of
February 04, 2020 – Milan, Italy and Morristown, NJ – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of
Milan, Italy and Morristown, NJ, USA, January 9, 2020 - Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of
The information on the following pages may be made available in the United States. By clicking on the link below, you agree that you are in the United States.
